scholarly journals Brain‐derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease

2021 ◽  
Author(s):  
E Chang ◽  
Jiongmei Wang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mouse Model ◽  
Neurotrophic Factor ◽  
Brain Derived Neurotrophic Factor ◽  
Motor Deficits

scholarly journals Focused ultrasound enhanced intranasal delivery of brain derived neurotrophic factor produces neurorestorative effects in a Parkinson’s disease mouse model

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Robin Ji ◽  
Morgan Smith ◽  
Yusuke Niimi ◽  
Maria E. Karakatsani ◽  
Maria F. Murillo ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Neurotrophic Factor ◽  
Focused Ultrasound ◽  
Neurodegenerative Disorder ◽  
Control Function ◽  
Early Stage ◽  
Brain Derived Neurotrophic Factor ◽  
Nigrostriatal Pathway

AbstractFocused ultrasound-enhanced intranasal (IN + FUS) delivery is a noninvasive approach that utilizes the olfactory pathway to administer pharmacological agents directly to the brain, allowing for a more homogenous distribution in targeted locations compared to IN delivery alone. However, whether such a strategy has therapeutic values, especially in neurodegenerative disorders such as Parkinson’s disease (PD), remains to be established. Herein, we evaluated whether the expression of tyrosine hydroxylase (TH), the rate limiting enzyme in dopamine catalysis, could be enhanced by IN + FUS delivery of brain-derived neurotrophic factor (BDNF) in a toxin-based PD mouse model. Mice were put on the subacute dosing regimen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), producing bilateral degeneration of the nigrostriatal pathway consistent with early-stage PD. MPTP mice then received BDNF intranasally followed by multiple unilateral FUS-induced blood-brain barrier (BBB) openings in the left basal ganglia for three consecutive weeks. Subsequently, mice were survived for two months and were evaluated morphologically and behaviorally to determine the integrity of their nigrostriatal dopaminergic pathways. Mice receiving IN + FUS had significantly increased TH immunoreactivity in the treated hemisphere compared to the untreated hemisphere while mice receiving only FUS-induced BBB opening or no treatment at all did not show any differences. Additionally, behavioral changes were only observed in the IN + FUS treated mice, indicating improved motor control function in the treated hemisphere. These findings demonstrate the robustness of the method and potential of IN + FUS for the delivery of bioactive factors for treatment of neurodegenerative disorder.

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset

2003 ◽  
Vol 353 (1) ◽  
pp. 75-77 ◽  
Author(s):  
Chen-Jee Hong ◽  
Hsiu-Chih Liu ◽  
Tsung-Yun Liu ◽  
Ching-Hua Lin ◽  
Chih-Ya Cheng ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurotrophic Factor ◽  
Age Of Onset ◽  
Brain Derived Neurotrophic Factor

scholarly journals Immature mDA neurons ameliorate motor deficits in a 6-OHDA Parkinson's disease mouse model and are functional after cryopreservation

2019 ◽  
Vol 41 ◽  
pp. 101617 ◽  
Author(s):  
Dominique Leitner ◽  
Mahesh Ramamoorthy ◽  
Marion Dejosez ◽  
Thomas P. Zwaka
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Mouse Model ◽  
Motor Deficits
Sign in / Sign up

Export Citation Format

Share Document